文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

预测胰腺头腺癌和远端胆管癌患者生存的预后评分。

A Prognostic Score for Predicting Survival in Patients With Pancreatic Head Adenocarcinoma and Distal Cholangiocarcinoma.

机构信息

Department of Surgical Sciences, Sapienza University of Rome, Rome, Italy.

Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy.

出版信息

In Vivo. 2021 Jan-Feb;35(1):507-515. doi: 10.21873/invivo.12285.


DOI:10.21873/invivo.12285
PMID:33402503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7880773/
Abstract

BACKGROUND/AIM: Survival of patients with pancreatic cancer remains poor despite improvements in therapeutic strategies. This study aims to create a novel preoperative score to predict prognosis in patients with tumors of the pancreaticobiliary head. PATIENTS AND METHODS: Data on 190 patients who underwent to pancreaticoduodenectomy at Sapienza University of Rome from January 2010 to December 2018 were retrospectively analyzed. After exclusion criteria, 101 patients were considered eligible for retrospective study. Preoperative biological, clinical and radiological parameters were considered. RESULTS: Pancreatic ductal adenocarcinoma [hazard ratio (HR)=1.995, 95% confidence intervaI (CI)=1.1-3.3; p=0.01], carbohydrate antigen 19.9 (CA 19.9) >230 U/ml (HR=2.414, 95% CI=2.4-1.5, p<0.0001) and Wirsung duct diameter >3 mm (HR=1.592, 95% CI=1.5-0.9; p=0.08) were the only parameters associated with poor prognosis. Through these parameters, a prognostic score (PHT score) was developed which predicted worst survival when exceeding 2 and better survival when ≤2. CONCLUSION: The PHT score may have a potential impact on predicting overall survival and consequently modulate the timing and type of treatment (up-front surgery vs. neoadjuvant therapy) patients are offered.

摘要

背景/目的:尽管治疗策略有所改进,胰腺癌患者的生存率仍然很差。本研究旨在创建一种新的术前评分,以预测胰头胆管肿瘤患者的预后。

患者与方法:回顾性分析了 2010 年 1 月至 2018 年 12 月在罗马 Sapienza 大学接受胰十二指肠切除术的 190 名患者的数据。排除标准后,101 名患者被认为适合回顾性研究。考虑了术前生物学、临床和影像学参数。

结果:胰腺导管腺癌(危险比 [HR]=1.995,95%置信区间 [CI]=1.1-3.3;p=0.01)、CA19.9>230 U/ml(HR=2.414,95% CI=2.4-1.5,p<0.0001)和 Wirsung 胆管直径>3mm(HR=1.592,95% CI=1.5-0.9;p=0.08)是与不良预后相关的唯一参数。通过这些参数,开发了一种预后评分(PHT 评分),当评分超过 2 分时预测最差生存,评分≤2 时预测更好的生存。

结论:PHT 评分可能对预测总生存有潜在影响,并因此调节患者接受的治疗( upfront surgery vs. neoadjuvant therapy)的时机和类型。

相似文献

[1]
A Prognostic Score for Predicting Survival in Patients With Pancreatic Head Adenocarcinoma and Distal Cholangiocarcinoma.

In Vivo. 2021

[2]
Pancreatic ductal adenocarcinoma and distal cholangiocarcinoma: a proposal of preoperative diagnostic score for differential diagnosis.

World J Surg Oncol. 2021-1-12

[3]
Intra-pancreatic distal cholangiocarcinoma and pancreatic ductal adenocarcinoma: a common short and long-term prognosis?

Updates Surg. 2021-4

[4]
Prognostic indicators following curative pancreatoduodenectomy for pancreatic carcinoma: A retrospective multivariate analysis of a single centre experience.

J BUON. 2016

[5]
[CA19-9 in intrahepatic cholangiocarcinoma : A diagnostic and prognostic armamentarium?].

Chirurg. 2018-6

[6]
Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer.

World J Surg Oncol. 2016-5-4

[7]
Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

JOP. 2012-3-10

[8]
[Application value of different lymph node staging system in predicting prognosis of patients with intrahepatic cholangiocarcinoma].

Zhonghua Wai Ke Za Zhi. 2020-4-1

[9]
Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.

Surgery. 2019-2-11

[10]
Prognostic impact of lymph node parameters in distal cholangiocarcinoma after pancreaticoduodenectomy.

World J Surg Oncol. 2020-10-8

引用本文的文献

[1]
Impact of radiological and pathological splenic vein involvement in patients with resectable pancreatic body or tail cancer.

Langenbecks Arch Surg. 2024-1-15

[2]
The consistencies and inconsistencies between distal cholangiocarcinoma and pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.

Front Oncol. 2022-12-12

[3]
The Systemic Inflammation-Based Prognostic Score Predicts Postoperative Complications in Patients Undergoing Pancreaticoduodenectomy.

Int J Gen Med. 2021-3-9

本文引用的文献

[1]
Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis.

Hepatobiliary Pancreat Dis Int. 2021-2

[2]
Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?

Updates Surg. 2020-6

[3]
Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials.

J Clin Med. 2020-4-15

[4]
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.

J Clin Oncol. 2020-6-1

[5]
CA19-9 for detecting recurrence of pancreatic cancer.

Sci Rep. 2020-1-28

[6]
Validation and clinical usefulness of pre- and postoperative systemic inflammatory parameters as prognostic markers in patients with potentially resectable pancreatic cancer.

Pancreatology. 2020-3

[7]
A Systematic Inflammation-based Model in Advanced Pancreatic Ductal Adenocarcinoma.

J Cancer. 2019-10-22

[8]
A combination of platelet-to-lymphocyte ratio and carbohydrate antigen 19-9 predict early recurrence after resection of pancreatic ductal adenocarcinoma.

Ann Transl Med. 2019-9

[9]
The Relationship Between Nutritional Status, Performance Status, and Survival Among Pancreatic Cancer Patients.

Nutr Cancer. 2019-7-4

[10]
Pancreatic Adenocarcinoma, Version 1.2019.

J Natl Compr Canc Netw. 2019-3-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索